Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 5/20 | 0.53 |
| ▸ | CES1 | P23141 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8021523 | 0.88 | SLC6A3 (0.45) | SLC6A3CES2CES1ALDH1A1CYP1A2 | |
| SCHEMBL6924827 | 0.84 | SLC6A3 (0.45) | SLC6A3CES2CES1GSK3B | |
| SCHEMBL8310512 | 0.82 | SLC6A3 (0.58) | SLC6A3CES2CES1HCAR1MDM2 | |
| SCHEMBL20702960 | 0.81 | CES2 (0.55) | SLC6A3CES2CES1ALDH1A1CYP1A2 | |
| SCHEMBL312334 | 0.80 | CES2 (0.57) | SLC6A3CES2CES1ALDH1A1CYP1A2 | |
| SCHEMBL1938267 | 0.78 | CES2 (0.50) | SLC6A3CES2CES1ALDH1A1CYP1A2 | |
| SCHEMBL4102288 | 0.77 | ALDH1A1 (0.51) | SLC6A3CES2CES1ALDH1A1CYP1A2 | |
| SCHEMBL4457802 | 0.77 | SLC6A3 (0.53) | SLC6A3CES2CES1HCAR1MDM2 | |
| SCHEMBL10728286 | 0.76 | TPMT (0.50) | SLC6A3ALDH1A1CYP1A2CYP2C9HCAR1 | |
| SCHEMBL635635 | 0.74 | TPMT (0.48) | SLC6A3ALDH1A1CYP1A2CYP2C9HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0426416-B1 | Novel morpholinol compounds, their preparation and use | WELLCOME FOUND (GB) | 1994-02-16 | — | — | EP | claimed |
| EP-0426416-A1 | Novel morpholinol compounds, their preparation and use | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-05-08 | — | — | EP | claimed |
| US-10919841-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | RES TRIANGLE INST (US) | 2018-08-02 | — | — | US | disclosed |
| US-9562001-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2017-02-07 | — | — | US | disclosed |
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE | 2012-03-22 | — | — | US | disclosed |
| EP-1220673-A2 | MORPHOLINOL DERIVATIVES FOR THE TREATMENT OF OBESITY | GLAXO GROUP LIMITED (GB) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001026641-A2 | MORPHOLINOL DERIVATIVES FOR THE TREATMENT OF OBESITY | GLAXO GROUP LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| EP-0475443-B1 | Chemical synthesis of oligonucleotides | HOECHST AG (DE) | 1994-10-19 | — | — | EP | disclosed |
| EP-0426416-B1 | Novel morpholinol compounds, their preparation and use | WELLCOME FOUND (GB) | 1994-02-16 | — | — | EP | disclosed |
| US-5104870-A | Psychological disorders | BURROUGHS WELLCOME CO. (US) | 1992-04-14 | — | — | US | disclosed |
| EP-0475443-A2 | Chemical synthesis of oligonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-03-18 | — | — | EP | disclosed |
| EP-0426416-A1 | Novel morpholinol compounds, their preparation and use | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885CES2 100/4885CES1 577/4885 |
| US-10919841-B2 | Monoamine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885CES2 100/4885CES1 577/4885 |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885CES2 100/4885CES1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.